EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Suspected remimazolam formulation-associated peri-induction anaphylaxis: two cases highlighting diagnostic complexity - Two case reports -

Hyun-Seong Lee, Min Woo Lee, Daeseok Oh

Anesthesia and Pain Medicine · 31.07.2026 · 21 (3) · 368-374

DOI: 10.17085/apm.26622 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Anesthesia and Pain Medicine, erschienen am 31.07.2026. Verfasst von Hyun-Seong Lee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Pain Medicine, Inje University Haeundae Paik Hospital, Busan, Korea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Reports of remimazolam formulation-associated anaphylaxis are increasing as its use expands. Between 2023 and 2025, we identified two severe reactions among 1,592 patients who received remimazolam at our institution.Case: A 65-year-old man (American Society of Anesthesiologists physical status [ASA PS] III) with end-stage renal disease developed profound hypotension without cutaneous signs after induction with 10 mg of remimazolam and peri-induction cefazedone administration. Surgery was cancelled due to persistent hypotension. Serum tryptase measured 6 h after the event was 38.0 μg/L; however, delayed skin testing was negative. Subsequent propofol-based anesthesia without cefazedone re-administration was uneventful. A 50-year-old woman (ASA PS I) developed hypotension and facial flushing within 2 min of receiving 10 mg of remimazolam. Although serum tryptase levels remained within the normal range (5.3 and 5.1 μg/L), delayed skin testing for remimazolam was positive.

Conclusions

Diagnosis of remimazolam formulation-associated hypersensitivity may remain inconclusive when based on a single diagnostic test. Accurate evaluation requires integrating timed tryptase, delayed skin testing, and careful evaluation of exposure history.

Schlagwörter

Stichwörter der Autor:innen

AnaphylaxisAnesthesia, generalDrug hypersensitivityRemimazolamTryptases

Autor:innen und Institutionen

  • Department of Anesthesiology and Pain Medicine, Inje University Haeundae Paik Hospital, Busan, Korea.

Zitieren

APA

Lee, H. S., Lee, M. W., & Oh, D. (2026). Suspected remimazolam formulation-associated peri-induction anaphylaxis: two cases highlighting diagnostic complexity - Two case reports -. Anesthesia and Pain Medicine, 21(3), 368-374. https://doi.org/10.17085/apm.26622

Vancouver

Lee HS, Lee MW, Oh D. Suspected remimazolam formulation-associated peri-induction anaphylaxis: two cases highlighting diagnostic complexity - Two case reports -. Anesthesia and Pain Medicine. 2026;21(3):368-374. doi:10.17085/apm.26622

BibTeX
@article{Lee2026,
  author = {Lee, Hyun-Seong and Lee, Min Woo and Oh, Daeseok},
  title = {Suspected remimazolam formulation-associated peri-induction anaphylaxis: two cases highlighting diagnostic complexity - Two case reports -},
  journal = {Anesthesia and Pain Medicine},
  year = {2026},
  volume = {21},
  number = {3},
  pages = {368--374},
  doi = {10.17085/apm.26622}
}
Kostenlos starten →